低分子肝素联合化疗治疗高凝状态晚期直肠癌对血栓标志物影响探究.docVIP

低分子肝素联合化疗治疗高凝状态晚期直肠癌对血栓标志物的影响研究 　　[摘要] 目的 探讨高凝状态晚期直肠癌患者采取低分子肝素联合化疗治疗对血栓标志物的影响。方法 整群选取68例于2014年5月―2015年5月期间该院接收的伴高凝状态晚期直肠癌患者，根据治疗方案不同分为对照组（单纯化疗，n=34）与实验组（低分子肝素联合化疗，n=34），观察两组疗效及两组患者纤维蛋白水平、D-二聚体含量在治疗前后的变化。结果 实验组较对照组临床有效率稍高（P0.05），分别为70.6%、64.7%，差异无统计学意义；治疗后，对照组纤维蛋白原水平无变化，D-二聚体含量较疗前显著要高（P0.05）。结论 高凝状态的晚期直肠癌患者采用低分子肝素联合化疗治疗，能有效改善患者高凝状态，但对直肠癌的远期疗效尚需进一步研究观察 [关键词] 血栓标志物；高凝状态；低分子肝素；晚期直肠癌 [中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2016）08（c）-0061-03 Clinical Effect of Low Molecular Weight Heparin and Chemotherapy in the Thrombosis Marker for Patients with Advanced Rectal Carcinoma and Hypercoagulability ZHANG Nian-hai Chemotherapy Section Ⅱ， The First Affiliated Hospital of Fujian Medical University， Fuzhou ， Fujian Province， 350004 China [Abstract] Objective To study the clinical effect of low molecular weight heparin and chemotherapy in the thrombosis marker for patients with advanced rectal carcinoma and hypercoagulability. Methods Group selection 68 patients with advanced rectal carcinoma and hypercoagulability treated from May 2014 to May 2015 in our hospital were selected. The subjects were divided into two groups according to different therapies， 34 cases each group. The control group took the chemotherapy； the test group took the low molecular weight heparin and chemotherapy. The clinical effect， the level of fibrinogen and D-dimer for two groups was observed. Results The clinical effective rate for test group （70.6%） was slightly higher than control group （64.7%） （P0.05）； For control group， the level of fibrinogen and D-dimmer was （4.96±1.42）g/L and（0.68±0.22）μg/L. The level of fibrinogen before and after treatment was not significantly different； the content of D-dimer was significantly higher than before （P0.05）.Conclusion For patients with advanced rectal carcinoma and hypercoagulability， the low molecular weight heparin and chemotherapy can improve the patient’s hypercoagulability. However， the long-term effect shall be further explored. [Key words